Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

doi:10.1200/JCO.2016.70.3223

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Apr 2017

Yang James Chih-Hsin, Ahn Myung-Ju, Kim Dong-Wan, Ramalingam Suresh S, Sequist Lecia V, Su Wu-Chou, Kim Sang-We, Kim Joo-Hang, Planchard David, Felip Enriqueta, Blackhall Fiona, Haggstrom Daniel, Yoh Kiyotaka, Novello Silvia, Gold Kathryn, Hirashima Tomonori, Lin Chia-Chi, Mann Helen, Cantarini Mireille, Ghiorghiu Serban, Jänne Pasi A

Abstract excerpt

Purpose Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing ( EGFRm) and T790M resistance mutations. AURA (NCT01802632) is a phase I/II clinical trial to determine the dose, safety, and efficacy of osimertinib. This article reports the results from the phase II extension component. Patients and Methods Patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Acrylamides

Share to Aniline Compounds

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to Disease-Free Survival

Share to Piperazines

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 28221867
DOI: 10.1200/JCO.2016.70.3223

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.PMID 28221867Read ↗

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.Semantic proximity Read ↗

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.Semantic proximity Read ↗

Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.Semantic proximity Read ↗

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.Semantic proximity Read ↗

Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.Semantic proximity Read ↗

The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis.Semantic proximity Read ↗

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.Semantic proximity Read ↗

Osimertinib in Advanced EGFR-T790M Mutation-positive Non-small Cell Lung Cancer Patients Treated Within the Special Use Medication Program in Spain. OSIREX-spanish Lung Cancer GroupSemantic proximity Read ↗

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.Semantic proximity Read ↗

FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.